A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
Enliven Therapeutics
Summary
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Description
This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female at least 18 years of age * Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML) * Prior treatment with 1 or more BCR::ABL1 TKI(s) * Failure or intolerance on the immediate prior TKI * Adequate end organ function as measured by blood tests Exclusion Criteria: * Known T315I mutation * Known second chronic phase of CML after previous progression to accelerated or blast phase * Any serious or uncontrolled medical disorder * QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec * Previous treatment with a hematopoietic stem-cell transplan…
Interventions
- DrugELVN-001
ELVN-001 orally daily
- DrugTKI
TKI orally daily
Locations (4)
- Winship Cancer InstituteAtlanta, Georgia
- Investigative Clinical Research of Indiana, LLCIndianapolis, Indiana
- Atlantic Health SystemMorristown, New Jersey
- Community Center Trials of UtahOgden, Utah